Skip to main content

Table 4 Comparison between the HCC and the normal control groups as regards different laboratory markers and plasma GSH

From: Relation between GSTP1 polymorphism and oxidative stress in patients with hepatocellular carcinoma

Group

Control

Patient

p value

 

Median

Range

Median

Range

 

ALT (U/L)

N: up to 41

25

21:30.8

51

35:67.5

< 0.001*

AST (U/L)

N: up to 40

26

20:30

82

54:114

< 0.001*

ALP (U/L)

N: up to 279

92.25

82:104.8

175

127:248

< 0.001*

ALB (g/dl)

N: 3.5:5.2

4

3.9:4.2

3.27

2.8:3.5

< 0.001*

INR

N: up to 1

1

1:1

1.24

1.1:1.3

< 0.001*

UREA (mg/dl)

N: 15-45

31

28:36

28

22:34.5

0.007*

AFP (ng/ml)

N: up to 10.5

1.85

1.2:2.7

117

16.3:1559.8

< 0.001*

LDH (U/L)

N: up to 250

116.5

102.3:130

207

172:248

< 0.001*

HB (gm/dl)

N: Male (13:18)

Female (12:16)

12.3

11.1:13.4

13

12:14

0.001*

TLC*10^9/L

N: 4-11

7.3

5.9:8.2

5.3

4.2:6.9

< 0.001*

PLT*10^9/L

N: 150-400

226.5

194.3:280.8

125

81:195

< 0.001*

GSH (mM/mg)

N: 684-2525

2010

1619.8:2310.8

1916.5

(862-3011)

0.152

  1. INR international normalization ratio, ALT alanine aminotransferase, AST aspartate aminotransferase, LDH lactate dehydrogenase, AFP alpha feto protein, ALP alkaline phosphatase, GSH reduced glutathione, ALB albumin, HB hemoglobin, TLC total leucocytic count, PLT platelets
  2. *Significant p value ≤ 0.05